Post-Market Clinical Follow-Up (PMCF) Under EU MDR: Plans, Studies, and the Complete Implementation Guide

What Is PMCF and Why It Matters Under EU MDR

Post-Market Clinical Follow-Up (PMCF) is the proactive and continuous process of collecting and evaluating clinical data about a medical device after it has been placed on the market. Its purpose is to confirm the safety and performance of the device throughout its expected lifetime, to identify previously unknown risks or emerging risks, to detect systematic misuse or off-label use, and to verify that the benefit-risk profile established during the pre-market phase remains acceptable in real-world clinical practice.

PMCF is not post-market surveillance (PMS) in general. It is one specific component within the broader PMS system — the component that deals specifically with clinical data. While PMS encompasses complaint handling, vigilance reporting, trend analysis, and other data streams, PMCF is focused on structured, planned activities designed to generate or collect clinical evidence.

And critically, PMCF under the EU Medical Device Regulation (EU) 2017/745 is not what it was under the Medical Device Directives.

The Fundamental Shift From MDD to MDR

Under the MDD, PMCF was referenced in MEDDEV 2.12/2 rev 2 as a guidance concept. It was not mandatory in the regulation itself with the same level of prescriptive detail. Many manufacturers — particularly those with Class I and IIa devices — treated PMCF as either optional or addressed it with a one-paragraph statement in the CER: "No PMCF activities are deemed necessary at this time." That approach was widely accepted by Notified Bodies for lower-risk devices with established clinical histories.

That era is over.

The MDR codifies PMCF as a regulatory requirement with specific, enforceable content expectations. Annex XIV Part B of the MDR sets out detailed requirements for the PMCF plan and the PMCF evaluation report. Article 61 ties clinical evaluation — and therefore PMCF — to the entire device lifecycle. Article 10(3) requires the clinical evaluation and its documentation, including the PMCF, to be updated throughout the life of the device.

The practical consequences are significant:

• Every device needs a PMCF plan. Not just Class III devices. Not just implantables. Every device placed on the EU market must have a documented PMCF plan, or a documented justification for why PMCF activities are not applicable — and that justification must be convincing. For most devices, "not applicable" will not hold up.
• PMCF is continuous, not one-time. The plan must define ongoing activities, not a single post-market study that concludes and gets filed away. PMCF feeds into CER updates, which occur on a schedule defined by device risk class.
• PMCF outputs have specific reporting requirements. The PMCF evaluation report is a defined document with expected contents, and it directly feeds into the CER, PSUR, and risk management file.
• Notified Bodies are auditing PMCF rigorously. Deficiency letters citing inadequate PMCF plans are among the most common findings in MDR conformity assessments. Notified Bodies have been given clear benchmarks, and they are using them.

Why PMCF Is Critical for All Device Classes

The proportionality principle under the MDR means that the depth and scope of PMCF activities should be commensurate with the risk class and the nature of the device. A Class I wound dressing does not need the same PMCF program as a Class III cardiac implant.

But proportionality does not mean exemption. Even for low-risk devices, the PMCF plan must exist. It must document the methods used to confirm ongoing safety and performance — even if those methods are limited to systematic literature surveillance and complaint trend analysis. The key is that the manufacturer has actively considered PMCF, documented a plan, and is executing that plan.

For higher-risk devices — Class III, implantable devices, devices incorporating medicinal substances, devices made from substances absorbed by the body — the MDR creates a strong expectation that PMCF will include active data collection, often in the form of PMCF studies.

Regulatory Framework for PMCF

Understanding where PMCF sits within the MDR's legal architecture is essential for building a compliant program. The requirements are distributed across multiple articles and annexes, and they interlock with the broader PMS and clinical evaluation framework.

MDR Articles

Article	Title	Relevance to PMCF
Article 61	Clinical evaluation	Establishes that clinical evaluation must be based on sufficient clinical evidence, and must be updated throughout the device lifetime. PMCF is the mechanism for generating ongoing clinical data.
Article 10(3)	General obligations of manufacturers	Requires manufacturers to update the clinical evaluation, including PMCF, throughout the life of the device.
Article 83	Post-market surveillance system	Requires manufacturers to establish a PMS system that includes PMCF as a component. PMCF data feeds into the PMS system.
Article 84	PMS plan	The PMS plan must reference the PMCF plan. The two documents are interconnected but distinct.
Article 85	PMS report (Class I)	For Class I devices, findings from PMCF activities are summarized in the PMS report, which is updated when necessary and made available to the competent authority upon request.
Article 86	Periodic Safety Update Report (Class IIa, IIb, III)	For higher-risk devices, PMCF findings feed into the PSUR, which is submitted to the Notified Body. The PSUR must include the conclusions of the PMCF evaluation report.
Article 62	Clinical investigations	Governs the conduct of clinical investigations, which may include PMCF studies. If a PMCF study qualifies as a clinical investigation under Article 62, it must comply with the full clinical investigation requirements (informed consent, ethics committee approval, sponsor obligations, etc.).

MDR Annexes

Annex	Relevance
Annex XIV Part B	The primary regulatory reference for PMCF. Sets out the requirements for the PMCF plan and PMCF evaluation report in detail.
Annex XIV Part A	Clinical evaluation requirements. The clinical evaluation process must incorporate PMCF findings.
Annex III	Technical documentation on post-market surveillance. The PMCF plan and PMCF evaluation report form part of this documentation.
Annex II	Technical documentation. Section 6.1 specifically references the clinical evaluation and PMCF.
Annex XV	Clinical investigations. Applicable when PMCF activities take the form of clinical investigations.

Key Guidance Documents

Document	Scope	Status
MEDDEV 2.12/2 rev 2	Post-market clinical follow-up studies	Legacy MDD guidance. While technically superseded by MDR provisions and MDCG guidance, it remains widely referenced for practical study design considerations.
MDCG 2020-7	Post-market clinical follow-up (PMCF) plan and PMCF evaluation report templates	The most important operational guidance for PMCF. Provides detailed templates for both the PMCF plan and the PMCF evaluation report. This is what Notified Bodies measure your documents against.
MDCG 2020-8	Post-market clinical follow-up (PMCF) evaluation report template for Class III and implantable devices	Supplementary template with enhanced detail for higher-risk devices.
MDCG 2020-5	Clinical evaluation — equivalence	Relevant when PMCF plans rely on clinical data from equivalent devices.
MDCG 2020-6	Sufficient clinical evidence for legacy devices	Critical guidance for devices transitioning from MDD to MDR — directly impacts PMCF planning.

MDD vs. MDR: PMCF Expectations Compared

Aspect	MDD (Old Framework)	MDR (Current Framework)
Legal basis	MEDDEV 2.12/2 rev 2 (guidance, not law)	Annex XIV Part B (legally binding)
Applicability	Primarily discussed for higher-risk devices	Required for all device classes
PMCF plan	Recommended but not prescriptively defined	Mandatory, with specific content requirements
PMCF evaluation report	No defined reporting format	Defined document with expected structure (MDCG 2020-7/8 templates)
Link to CER	Referenced, but CER update frequency was vague	Explicit — PMCF findings must be reflected in CER updates at defined intervals
Notified Body scrutiny	Variable — many NBs accepted minimal PMCF justifications	Rigorous — PMCF is a standard audit focus area
"No PMCF needed" justification	Commonly accepted for low-risk devices	Rare — must be comprehensively justified; blanket exemptions are not accepted

The PMCF Plan

The PMCF plan is the strategic document that defines what clinical data the manufacturer will collect after market placement, how that data will be collected, when, and why. It is not a generic procedural document — it is device-specific (or device-group-specific if devices share the same intended purpose, design, and risk profile).

Who Needs a PMCF Plan?

Every manufacturer placing a medical device on the EU market under the MDR. There are no exemptions by device class. Annex XIV Part B, Section 6.1 of Annex II, and Article 10(3) collectively require that the clinical evaluation — including PMCF — is maintained throughout the device lifetime.

For devices where the manufacturer determines that PMCF activities beyond routine PMS (complaint monitoring, literature surveillance) are not warranted, the PMCF plan must still exist. It must document the rationale for this determination, demonstrating that:

• The device has an extensive clinical history
• The safety and performance are well-established in published literature
• The residual risks identified in the risk management file do not require active clinical follow-up
• There are no clinical evidence gaps that need to be addressed

Even in these cases, the PMCF plan should define the literature surveillance strategy that will be used to monitor for new clinical data on an ongoing basis.

PMCF Plan Contents Per Annex XIV Part B

Annex XIV Part B specifies the contents of the PMCF plan. The following structure aligns with both the regulatory requirements and the MDCG 2020-7 template.

1. Device Description and Scope

The plan must identify the device (or device group), its intended purpose, the target patient population, the intended users, the indications, and the contraindications. It should reference the risk classification, the applicable GSPRs, and the current status of the clinical evaluation.

2. Objectives

The PMCF plan must clearly state what the manufacturer intends to achieve through PMCF activities. Annex XIV Part B specifies the following objectives:

• To confirm the safety and performance of the device throughout its expected lifetime
• To identify previously unknown side-effects and monitor the identified side-effects and contraindications
• To identify and analyze emergent risks on the basis of factual evidence
• To ensure the continued acceptability of the benefit-risk ratio
• To identify possible systematic misuse or off-label use of the device, with a view to verifying that the intended purpose is appropriate

3. General Methods

These are the ongoing, systematic data collection activities that form the baseline of PMCF:

Literature surveillance — A defined, repeatable literature search strategy that monitors for new publications relevant to the device, its intended purpose, its components, and the clinical condition it addresses. The search protocol should define databases, search terms, frequency, and appraisal criteria. This is not the same as the initial literature review conducted for the CER — it is a periodic update that captures new evidence as it emerges.

Complaint and vigilance data analysis — Systematic review of complaint data, serious incident reports, field safety corrective actions, and trend reports. The analysis should look for patterns that suggest previously unidentified risks or changes in the device's benefit-risk profile.

Registry data — Where applicable, participation in or analysis of data from device registries. Registries can provide long-term outcomes data that is difficult to obtain through other means, particularly for implantable devices.

Consultation of specialist databases — Monitoring of regulatory databases such as MAUDE (FDA), BfArM device database, MHRA alerts, and (when fully functional) EUDAMED for safety information about the device or equivalent/similar devices.

4. Specific Methods

These are targeted data collection activities designed to address specific clinical questions or evidence gaps:

PMCF studies — Prospective or retrospective clinical studies designed to generate clinical data about the device in its post-market phase. These are discussed in detail in the next section.

Surveys and questionnaires — Structured data collection from healthcare professionals and/or patients regarding device performance, usability, and adverse events. Useful for capturing user experience data and identifying usability-related risks.

Collaboration with clinical experts or user groups — Formal or informal feedback mechanisms with specialist clinicians who use the device, designed to capture expert opinion on device performance in clinical practice.

5. Reference to GSPRs and Risk Management

The PMCF plan must explicitly reference the relevant General Safety and Performance Requirements (GSPRs) that the PMCF activities are intended to address. It must also reference the risk management file and explain how PMCF outputs feed back into risk management.

This is not a formality. The PMCF plan should map specific PMCF activities to specific GSPRs and specific residual risks. For example:

GSPR	Risk / Clinical Question	PMCF Activity	Acceptance Criteria
GSPR 1 (benefit-risk)	Long-term implant survival rate	Registry data analysis (National Joint Registry)	10-year survival rate greater than or equal to 95%
GSPR 8 (infection risk)	Post-operative infection rate	PMCF study — prospective multicenter	Infection rate below 2% at 90 days post-implant
GSPR 17 (IFU adequacy)	User errors during device setup	Structured survey of clinical users	Critical use error rate below 1%

6. Schedule and Milestones

The PMCF plan must define the timeline for activities — when studies will begin, when interim analyses will be conducted, when reports will be generated, and how frequently the plan itself will be reviewed and updated.

For Class III and implantable devices, Notified Bodies expect to see a multi-year schedule with defined interim milestones. A vague statement like "ongoing literature surveillance will be conducted" is insufficient.

7. Acceptance Criteria

This is one of the most frequently cited deficiencies in PMCF plans. The plan must define, in advance, the criteria by which the manufacturer will determine whether PMCF findings confirm or challenge the device's safety and performance profile.

Acceptance criteria should be:

• Specific and measurable — Not "device performs well" but "complication rate remains below 3% at 12 months"
• Linked to the clinical evaluation — Referenced back to the endpoints and conclusions in the CER
• Actionable — If acceptance criteria are not met, the plan should define what happens next (additional data collection, risk management update, field safety corrective action, etc.)

8. PMCF Plan Template Structure

The following outline synthesizes the MDCG 2020-7 template with practical implementation requirements:

1. Introduction and scope
2. Device description and intended purpose
3. Summary of clinical evaluation status and identified evidence gaps
4. PMCF objectives
5. Reference to applicable GSPRs
6. Reference to risk management file and identified residual risks
7. General PMCF methods
   • 7.1 Literature surveillance protocol
   • 7.2 Complaint and vigilance data analysis
   • 7.3 Registry data (if applicable)
   • 7.4 Database monitoring
8. Specific PMCF methods
   • 8.1 PMCF study synopsis (if applicable)
   • 8.2 Surveys / questionnaires (if applicable)
   • 8.3 Other specific activities
9. Acceptance criteria (tabulated per clinical question / GSPR)
10. Schedule, milestones, and reporting intervals
11. Roles and responsibilities
12. References

PMCF Studies

PMCF studies are the most resource-intensive — and often the most valuable — component of a PMCF program. Not every device requires a PMCF study, but manufacturers should not assume that literature surveillance and complaint analysis alone will satisfy Notified Body expectations, particularly for higher-risk devices.

Types of PMCF Studies

Prospective Clinical Investigations (Article 62)

These are forward-looking studies where the manufacturer defines a protocol, enrolls subjects, and collects data over a defined period. They represent the highest level of PMCF evidence.

If a prospective PMCF study meets the definition of a clinical investigation under Article 2(45) of the MDR — i.e., it is a systematic investigation involving human subjects undertaken to assess the safety or performance of a device — it must comply with the requirements of Article 62 and Annex XV. This means:

• Ethics committee approval is required
• Informed consent from subjects
• Registration in EUDAMED (when the relevant module is functional)
• Sponsor obligations (including monitoring, adverse event reporting, and study insurance)
• A clinical investigation plan that meets Annex XV requirements

Not all prospective data collection qualifies as a clinical investigation under Article 62. The distinction hinges on whether the study imposes additional procedures or burden on the subject beyond normal clinical use. A manufacturer collecting outcome data from medical records for patients who received a device during routine clinical care — without any additional visits, tests, or interventions — may argue that this constitutes a "non-interventional" study that falls outside Article 62 scope. However, this distinction is nuanced and competent authority interpretations vary across member states. When in doubt, consult the relevant competent authority.

Retrospective Studies Using Existing Clinical Data

These studies analyze clinical data that has already been generated — for example, medical records, imaging data, or institutional databases from patients who have already been treated with the device. They are faster and less costly than prospective studies but are limited by the quality and completeness of the existing data.

Retrospective studies are particularly useful for legacy devices transitioning from MDD to MDR, where historical clinical data exists but was never formally collected under a structured study protocol.

Registry-Based Studies

Device registries — particularly national registries for implantable devices (e.g., the National Joint Registry in the UK, the Swedish Hip Arthroplasty Register, the German Endoprosthesis Registry) — provide long-term, real-world performance data that is extremely difficult to replicate through manufacturer-sponsored studies.

Registry-based PMCF studies involve either participating in an existing registry or analyzing data from registries that already include the manufacturer's device. The advantages are large sample sizes, long follow-up durations, and independent data collection. The disadvantages are limited control over data variables and potential delays in data access.

For implantable devices, Notified Bodies increasingly expect to see registry participation as part of the PMCF plan.

Surveys and Structured Feedback

Surveys distributed to healthcare professionals and/or patients can capture data on device usability, user satisfaction, training effectiveness, and perceived performance. They are particularly useful for addressing GSPRs related to usability (GSPR 5 on ergonomic features) and information supplied with the device (GSPR 23 on IFU).

Surveys have inherent limitations — response bias, self-reporting inaccuracies — but they fill a gap that other study types cannot address: the user's subjective experience with the device.

Comparison of PMCF Study Types

Study Type	Strengths	Limitations	Best Suited For	Typical Duration
Prospective clinical investigation	Highest evidence quality; controlled data collection; pre-defined endpoints	Most expensive and time-consuming; Article 62 compliance required; ethics approval needed	Class III, implantables, novel devices, devices with limited clinical history	1 to 5+ years
Retrospective study	Faster execution; lower cost; uses existing data	Limited by data quality and completeness; potential for selection bias; may lack key variables	Legacy devices; devices with extensive clinical history; supplementary evidence	3 to 12 months (data analysis phase)
Registry-based study	Large sample sizes; long follow-up; real-world data; independent collection	Limited variable control; data access delays; may not capture device-specific details; registry participation fees	Implantable devices; orthopedic, cardiac, and vascular devices	Ongoing (annual data extracts)
Surveys / questionnaires	Low cost; captures user experience; addresses usability GSPRs	Response bias; self-reporting limitations; not suitable for clinical safety endpoints	Usability assessment; IFU adequacy; training effectiveness	1 to 6 months per cycle

PMCF Study Design Considerations

When designing a PMCF study, the following elements must be addressed in the study protocol or synopsis:

Clinical endpoints: Define primary and secondary endpoints that directly address the clinical questions identified in the PMCF plan. Primary endpoints should be clinically meaningful — device-related complication rates, procedure success rates, patient-reported outcomes (e.g., validated PROMs such as EQ-5D, VAS pain scores), or device survival rates.

Sample size: The sample size must be justified statistically. For safety endpoints, sample size calculations should account for the expected event rate, the precision required for the confidence interval, and the follow-up period. The "three times the rule of three" approach (i.e., enrolling at least 3/p subjects, where p is the expected complication rate) is a common starting point but should be supplemented with formal power calculations. Sample sizes that are too small to detect meaningful differences are a frequent audit finding.

Follow-up duration: The duration must be appropriate for the device's expected lifetime and the endpoints being measured. For implantable devices, follow-up durations of 5 to 10 years are typically expected. For short-term-use devices, shorter durations are appropriate but must be justified.

Statistical analysis plan: Pre-define the statistical methods, handling of missing data, interim analysis triggers, and subgroup analyses. Bayesian approaches can be useful for PMCF studies where prior data exists and the goal is to update the evidence base rather than test a novel hypothesis.

Sites and investigators: For multicenter studies, define site selection criteria. Include a range of clinical settings (academic and community) to enhance generalizability.

When Is a PMCF Study Required?

The MDR does not mandate PMCF studies for every device. However, the practical reality is that PMCF studies are expected or strongly recommended for:

• All Class III devices — The combination of high-risk classification, Annex XIV Part B requirements, and Notified Body expectations means that a Class III device without a PMCF study (either planned or ongoing) will face intense scrutiny.
• Implantable devices — Regardless of risk class, implantable devices require long-term safety and performance monitoring that literature surveillance alone rarely provides.
• Devices with limited clinical data — Novel devices, devices in new indication areas, or devices where equivalence to a well-documented predicate cannot be established.
• Devices where residual risks require ongoing monitoring — If the risk management file identifies residual risks that cannot be fully characterized without post-market clinical data.
• Devices where the state of the art is evolving — If new clinical evidence, alternative treatments, or competing devices are changing the accepted standard of care.

For many Class IIa and some Class IIb devices with well-established safety profiles and extensive published literature, a PMCF plan based on systematic literature surveillance, complaint analysis, and possibly structured surveys may be sufficient without a formal PMCF study. But this must be justified in the PMCF plan.

Ethics Committee and Institutional Review Considerations

If a PMCF study qualifies as a clinical investigation under Article 62, ethics committee (EC) / institutional review board (IRB) approval is required. Key considerations:

• EC approval must be obtained before enrolling any subjects.
• Approval timelines vary significantly across EU member states — from 30 to 60 days in most countries, but substantially longer in some.
• Multi-country studies require separate EC approvals in each country (the MDR's clinical investigation application process through EUDAMED is intended to streamline this, but the practical reality in 2026 remains fragmented).
• Even for non-interventional studies that may not require full Article 62 compliance, institutional review or data protection approval may still be needed, depending on the member state and the institution's policies.
• GDPR requirements for processing patient data must be addressed in the study protocol, regardless of whether the study is interventional.

PMCF Evaluation Report

The PMCF evaluation report is the output document of PMCF activities. It summarizes the results of all PMCF data collection and analysis, draws conclusions about the device's safety and performance, and identifies any actions required.

Structure and Contents

The MDCG 2020-7 and MDCG 2020-8 templates provide the expected structure. Notified Bodies review PMCF evaluation reports against these templates. A report that does not address the expected elements will generate deficiency findings.

The PMCF evaluation report should include:

1. Introduction — Device identification, intended purpose, scope of the PMCF evaluation, reference to the PMCF plan
2. Summary of PMCF activities conducted — What was done during the reporting period (literature searches performed, studies conducted, surveys distributed, registry data analyzed)
3. Results of PMCF activities — Detailed presentation of findings:
   • Literature surveillance results: new publications identified, appraisal findings, relevant clinical data
   • PMCF study results: interim or final results, statistical analysis
   • Complaint and vigilance trend analysis
   • Registry data analysis
   • Survey results
4. Analysis and discussion — Interpretation of findings in the context of the clinical evaluation, comparison against acceptance criteria defined in the PMCF plan
5. Conclusions on safety and performance — Explicit statements about whether PMCF findings confirm the device's safety and performance profile
6. Conclusions on benefit-risk — Assessment of whether the benefit-risk ratio remains acceptable
7. Identified new risks or changes to existing risks — If PMCF findings reveal new safety signals or changes in the risk profile, these must be documented
8. Actions and recommendations — Required updates to the CER, risk management file, IFU, PMCF plan, or any other technical documentation
9. PMCF plan update — Confirmation that the PMCF plan remains appropriate or identification of needed modifications

What Notified Bodies Expect

Based on published MDCG guidance and industry experience with NB audits, the following are key NB expectations for the PMCF evaluation report:

• It is not a copy of the CER. The PMCF evaluation report should present new data and analysis since the last reporting period. It supplements the CER — it does not duplicate it.
• Acceptance criteria are addressed. The report must explicitly compare PMCF findings against the acceptance criteria defined in the PMCF plan. If criteria are met, state so. If not, explain why and describe the corrective actions.
• Literature searches are documented. The search methodology, databases used, date of search, number of results screened, and number of publications included/excluded must be documented — with the same rigor expected for the CER literature search.
• The report drives action. If PMCF findings indicate new risks, changing benefit-risk, or performance issues, the report must clearly state what actions the manufacturer will take. A report that identifies potential safety signals but does not recommend action will be flagged.

Update Frequency

The MDR does not specify a standalone update frequency for the PMCF evaluation report. However, the report feeds into the CER, and the CER update cycle is defined:

Device Class	CER Update Frequency	PMCF Evaluation Report Update
Class I	When necessary, and at least when new relevant information emerges	At least aligned with CER updates
Class IIa	At least every 2 years (via PSUR cycle)	At least every 2 years
Class IIb	At least annually (via PSUR cycle)	At least annually
Class III	At least annually (via PSUR cycle)	At least annually
Implantable (any class)	At least annually (via PSUR cycle)	At least annually

In practice, for devices with active PMCF studies, the evaluation report should be updated whenever new study data becomes available — even if this is more frequent than the minimum cycle.

Relationship Between PMCF, PMS, Vigilance, and Clinical Evaluation

One of the most common sources of confusion — and audit findings — is the relationship between PMCF and the other post-market processes. These are distinct but deeply interconnected systems, and manufacturers who treat them in silos will have compliance gaps.

The Continuous Improvement Loop

The MDR establishes a continuous feedback loop in which post-market data flows back into the device's pre-market documentation:

PMS system (Article 83) is the overarching framework that collects all post-market data: complaints, vigilance reports, literature, registry data, and PMCF study results.

PMCF (Annex XIV Part B) is the clinical data-focused subset of PMS. It collects and evaluates clinical evidence specifically.

Clinical Evaluation Report (Annex XIV Part A, Article 61) is updated with PMCF findings. The CER is not a static document — it is a living analysis that must incorporate new clinical evidence as it becomes available.

Risk Management (ISO 14971, referenced throughout the MDR) is updated when PMCF or PMS data identifies new hazards, changes in probability or severity of harm, or changes in the benefit-risk profile.

PSUR / PMS Report (Articles 85-86) summarizes PMS and PMCF findings for regulatory reporting. The PSUR for Class IIa, IIb, and III devices is submitted to the Notified Body and must include conclusions from the PMCF evaluation report.

Instructions for Use / Labeling are updated when PMCF findings necessitate changes to warnings, contraindications, or use instructions.

The flow is bidirectional and cyclical:

PMCF Plan defines what clinical data to collect and how. PMCF activities generate clinical data. PMCF Evaluation Report analyzes the data and draws conclusions. These conclusions feed into the CER update, which may identify new clinical questions or evidence gaps. Those gaps feed back into the PMCF Plan update, which defines new or modified PMCF activities. Simultaneously, PMCF findings feed into the risk management file (potentially triggering design changes, labeling updates, or field safety corrective actions) and the PSUR (for regulatory reporting to Notified Bodies and competent authorities).

Data Flow Map

Data Source	Feeds Into	Action Triggered
PMCF study results	PMCF Evaluation Report, CER, Risk Management File	CER update, risk re-assessment, potential GSPR review
Literature surveillance	PMCF Evaluation Report, CER	CER update, state-of-the-art re-assessment
Complaint data	PMS system, PMCF Evaluation Report (clinical complaints)	Trend analysis, vigilance reporting (if applicable), CAPA
Vigilance reports	PMS system, PMCF Evaluation Report	Risk management update, FSCA if warranted
Registry data	PMCF Evaluation Report, CER	Long-term performance validation, CER update
User surveys	PMCF Evaluation Report	IFU updates, training material revisions, usability risk updates

Common Integration Failures

The following integration failures are frequently identified during Notified Body audits:

• PMCF evaluation report exists but CER is not updated. The PMCF evaluation report identifies new clinical data, but the CER continues to reference outdated evidence.
• Complaint data is analyzed for vigilance but not for PMCF. Clinical complaint data is a valuable PMCF input, but many manufacturers only analyze complaints through the vigilance lens without feeding clinically relevant findings into the PMCF evaluation.
• Risk management file is static. PMCF findings that suggest new or changed risks are documented in the PMCF evaluation report but never reflected in the risk management file.
• PSUR does not reference PMCF conclusions. The PSUR summarizes PMS data but omits or inadequately references the PMCF evaluation report conclusions.

PMCF for Different Device Risk Classes

The proportionality principle means that PMCF expectations scale with risk. But the baseline — a documented PMCF plan and evaluation report — applies to all classes.

Class I Devices

Typical PMCF activities: Systematic literature surveillance, complaint trend analysis, monitoring of regulatory databases for safety signals related to the device type.

PMCF study expectation: Generally not required unless the device has a novel feature, limited clinical history, or an evolving state of the art. However, a manufacturer must document why a PMCF study is not necessary.

Reporting: PMCF evaluation report feeds into the PMS report (Article 85). Update frequency is "when necessary" but should be at least every 2 to 3 years as a practical minimum.

Notified Body scrutiny: Lower, since Class I devices (except Class I with measuring function, sterile, or reusable surgical instruments) are self-certified. However, competent authority market surveillance audits may review PMCF documentation.

Class IIa Devices

Typical PMCF activities: Literature surveillance, complaint analysis, and often targeted data collection such as surveys or analysis of institutional outcome data. Registry participation where applicable.

PMCF study expectation: Case-by-case. For well-established device types with extensive published literature (e.g., standard surgical instruments, established wound care products), a PMCF study may not be needed. For devices with limited clinical data or novel features, a study is expected.

Reporting: PMCF evaluation report feeds into the PSUR. Update at least every 2 years.

Notified Body scrutiny: Moderate. The NB will review the PMCF plan and evaluation report during conformity assessment and surveillance audits. Expect questions about the rationale if no PMCF study is included.

Class IIb Devices

Typical PMCF activities: Comprehensive literature surveillance, complaint and vigilance trend analysis, and in most cases, active data collection through PMCF studies, registry participation, or structured surveys.

PMCF study expectation: For Class IIb implantable devices, a PMCF study is strongly expected. For non-implantable Class IIb devices, the expectation depends on the device's clinical history and the adequacy of existing clinical evidence.

Reporting: PMCF evaluation report feeds into the PSUR. Update at least annually.

Notified Body scrutiny: High. Class IIb devices, particularly implantables, receive close NB scrutiny on PMCF. The NB will assess whether the PMCF plan is adequate relative to the residual risks and clinical evidence gaps.

Class III Devices

Typical PMCF activities: All methods — literature surveillance, complaint and vigilance analysis, registry participation, and PMCF studies (often prospective clinical investigations).

PMCF study expectation: A PMCF study is expected for essentially all Class III devices. Notified Bodies will challenge a Class III PMCF plan that relies solely on literature surveillance and complaint analysis. The study should address long-term safety, rare adverse events, and ongoing benefit-risk confirmation.

Reporting: PMCF evaluation report feeds into the PSUR and the Summary of Safety and Clinical Performance (SSCP). Update at least annually.

Notified Body scrutiny: Very high. For Class III devices, the NB conducts a clinical evaluation assessment as part of conformity assessment (per Article 56 and MDCG 2020-13 CEAR template). PMCF is a central component of this assessment.

Implantable Device-Specific Requirements

Implantable devices of any risk class face enhanced PMCF expectations:

• Long-term follow-up data is expected — typically covering the expected lifetime of the implant
• Registry participation is strongly encouraged and, for certain device types (e.g., orthopedic implants, cardiac devices), effectively mandatory
• The SSCP must be prepared and made publicly available (for Class III and implantable devices) and must reflect PMCF findings
• Article 61(4) creates a strong presumption that clinical investigation data is needed for implantable devices, which directly impacts PMCF expectations

Common PMCF Challenges and Pitfalls

Based on Notified Body deficiency findings, competent authority enforcement trends, and industry experience, the following are the most frequent PMCF-related problems encountered by manufacturers.

1. Insufficient Planning

The PMCF plan is generic — a copy-paste template that does not address the specific device, its clinical context, or its identified risks. It reads like a QMS procedure rather than a device-specific strategy. Acceptance criteria are vague or absent. The schedule is undefined.

How to avoid it: Write the PMCF plan as a standalone strategic document specific to the device. Cross-reference the risk management file and CER. Define measurable acceptance criteria.

2. Over-Reliance on Literature Alone

For higher-risk devices, manufacturers rely exclusively on literature surveillance as the PMCF method without justifying why active data collection is not needed. Literature surveillance is necessary but rarely sufficient for Class IIb and Class III devices.

How to avoid it: Conduct a gap analysis against the CER and risk management file. If clinical questions remain that published literature cannot answer — particularly questions about long-term safety, rare events, or device-specific performance — active data collection is needed.

3. Inadequate Sample Sizes

PMCF studies are designed with sample sizes that are too small to detect clinically meaningful differences or to provide useful safety data. A common mistake is enrolling 30 to 50 patients for a study intended to characterize a complication with an expected incidence of less than 1%.

How to avoid it: Perform formal sample size calculations based on the endpoints and expected event rates. Document the assumptions and the statistical methodology.

4. Poor Integration With Complaint Handling

Complaint data contains clinically relevant information that should feed into PMCF, but many manufacturers maintain separate silos for complaints and PMCF. Clinical complaints are processed through the quality system but never analyzed in the PMCF context.

How to avoid it: Establish a defined process for flagging clinically relevant complaints and routing them to the PMCF evaluation. Include complaint trend analysis as a standing item in the PMCF evaluation report.

5. Failing to Update the CER

PMCF activities are conducted, a PMCF evaluation report is written, but the CER is not updated to incorporate the new clinical evidence. The CER and the PMCF evaluation report tell different stories.

How to avoid it: Align PMCF evaluation report and CER update cycles. Build a process trigger: every PMCF evaluation report update should initiate a CER review, and the CER should explicitly reference the latest PMCF evaluation report.

6. No Action on Findings

The PMCF evaluation report identifies potential safety signals or trends but does not translate them into concrete actions — risk management updates, labeling changes, design modifications, or additional data collection. The report becomes a descriptive exercise rather than a driver of improvement.

How to avoid it: Every PMCF evaluation report must include an "Actions and Recommendations" section with specific, assigned, and tracked follow-up items.

7. Notified Body Audit Findings Related to PMCF

The most common PMCF-related NB deficiency categories, based on published and industry-reported data:

Deficiency Category	Frequency	Typical Root Cause
PMCF plan missing or inadequate	Very common	Manufacturer did not prioritize PMCF planning; used generic template
Acceptance criteria not defined	Very common	Manufacturer treated PMCF plan as procedural rather than strategic
No PMCF evaluation report	Common	PMCF plan exists but was never executed
PMCF evaluation report not linked to CER	Common	Separate teams manage CER and PMCF without coordination
PMCF study not planned for high-risk device	Common	Manufacturer underestimated NB expectations for device risk class
Literature search methodology inadequate	Moderately common	Search not systematic, not reproducible, or too narrow in scope

PMCF for Legacy Devices

The transition from MDD to MDR creates specific PMCF challenges for legacy devices — devices that were certified under the MDD and are now seeking MDR certification.

Clinical Evidence Gaps

Many MDD-certified devices have limited formal clinical evidence. Under the MDD, clinical evaluation requirements were less prescriptive, and many devices (particularly Class I and IIa) were certified with minimal clinical data — sometimes relying entirely on equivalence arguments supported by a small literature review.

Under the MDR, the clinical evaluation must be comprehensive. PMCF is one of the mechanisms for closing the gap between MDD-era evidence and MDR expectations.

How to Build a PMCF Plan When Historical Data Is Limited

For legacy devices, the PMCF plan may need to be more extensive than for devices that underwent a full MDR pre-market clinical evaluation. The following approach is recommended:

1. Conduct a clinical evidence gap analysis. Compare the existing CER (even if it is an MDD-era CER) against MDR requirements. Identify which GSPRs lack adequate clinical evidence support.

2. Assess available post-market data. Legacy devices have been on the market for years — sometimes decades. There is likely a wealth of complaint data, vigilance reports, and possibly institutional outcome data that has never been systematically analyzed for clinical evaluation purposes. Conduct a comprehensive retrospective analysis.

3. Prioritize evidence gaps. Not all gaps can be addressed simultaneously. Prioritize based on risk: which gaps relate to the most significant residual risks? Which are most likely to be challenged by the Notified Body?

4. Design PMCF activities to close priority gaps. This may include:

   • A comprehensive retrospective study using existing clinical data
   • A prospective PMCF study for gaps that cannot be addressed retrospectively
   • Enhanced literature surveillance targeting specific clinical questions
   • Registry enrollment if applicable

5. Document the transition strategy. The PMCF plan should explicitly acknowledge the device's MDD history and describe the strategy for building the clinical evidence base to MDR standards.

Using Equivalence Arguments

MDCG 2020-5 has tightened equivalence requirements under the MDR. For legacy devices that previously relied on equivalence to support clinical evaluation, the PMCF plan should address:

• Whether equivalence can still be demonstrated under MDR criteria (clinical, technical, and biological equivalence, with access to the equivalent device's technical documentation for devices from a different manufacturer)
• If equivalence can no longer be maintained, what PMCF activities will generate device-specific clinical data to replace equivalence-based evidence
• Timeline for transitioning from equivalence-dependent evidence to device-specific evidence

MDCG 2020-6 (sufficient clinical evidence for legacy devices) provides a framework for this assessment and should be referenced in the PMCF plan.

Practical PMCF Implementation Roadmap

The following step-by-step roadmap is designed for manufacturers implementing a PMCF program from scratch or upgrading an MDD-era approach to MDR compliance.

Step 1: Gap Analysis (Months 1-2)

• Review the current CER and identify clinical evidence gaps
• Review the risk management file and identify residual risks requiring post-market clinical monitoring
• Assess available post-market data (complaints, vigilance, literature, registry data)
• Determine which GSPRs lack adequate clinical evidence support
• Benchmark PMCF requirements against device risk class and NB expectations

Step 2: PMCF Plan Development (Months 2-3)

• Draft the PMCF plan using the MDCG 2020-7 template as the structural framework
• Define PMCF objectives linked to specific clinical questions and GSPRs
• Select appropriate PMCF methods (general and specific) with rationale
• Define acceptance criteria for each clinical question
• Establish the schedule, milestones, and reporting intervals
• Assign roles and responsibilities
• Review and approve through the QMS document control process

Step 3: Study Design and Protocol Development (Months 3-6, if applicable)

• Develop the PMCF study protocol (if a PMCF study is planned)
• Conduct sample size calculations and define statistical analysis plan
• Identify study sites and investigators
• Prepare ethics committee submissions
• Develop case report forms and data collection tools
• Establish data management and quality assurance processes

Step 4: PMCF Execution — Ongoing

Literature surveillance: Execute the literature search protocol at defined intervals (at least annually, more frequently for higher-risk devices or rapidly evolving fields). Document search results, screen and appraise new publications, and flag clinically significant findings.

Complaint and vigilance analysis: Implement a systematic process for routing clinically relevant complaint data to the PMCF evaluation. Conduct trend analysis at defined intervals.

PMCF study execution: Enroll subjects, collect data, conduct monitoring visits, manage adverse event reporting, and perform interim analyses per the study protocol.

Registry data collection: Extract and analyze registry data at defined intervals.

Step 5: PMCF Evaluation Report (Per Defined Schedule)

• Compile and analyze all PMCF data collected during the reporting period
• Compare findings against acceptance criteria
• Draw conclusions on safety, performance, and benefit-risk
• Identify required actions (CER update, risk management update, labeling changes, additional PMCF activities)
• Document in the PMCF evaluation report using the MDCG 2020-7/8 template structure

Step 6: Feedback Loop — Continuous

• Update the CER to incorporate PMCF findings
• Update the risk management file if new hazards or changed risk levels are identified
• Update the PSUR to include PMCF conclusions
• Revise the PMCF plan if new clinical questions emerge, if acceptance criteria need adjustment, or if additional PMCF activities are warranted
• Revise labeling and IFU if PMCF findings necessitate changes

Step 7: Management Review and Audit Readiness

• Include PMCF status in management review inputs
• Maintain audit-ready documentation: PMCF plan, PMCF evaluation reports, study protocols and reports, literature search records, and traceability to CER and risk management updates
• Conduct internal audits of the PMCF process to identify gaps before the Notified Body does

PMCF and IVDR: PMCF vs. PMPF

The In Vitro Diagnostic Regulation (EU) 2017/746 introduces a parallel concept for IVD devices: Post-Market Performance Follow-Up (PMPF). While structurally similar to PMCF, there are important differences that IVD manufacturers must understand.

Key Similarities

• Both require a documented plan, ongoing execution, and an evaluation report
• Both feed into the clinical evaluation (for devices) or performance evaluation (for IVDs) and into the PMS system
• Both are proportionate to device risk class
• Both are subject to Notified Body review for devices requiring NB involvement

Key Differences

Aspect	PMCF (MDR — Medical Devices)	PMPF (IVDR — IVD Devices)
Regulatory basis	Annex XIV Part B of MDR	Annex XIII Part B of IVDR
Terminology	Post-Market Clinical Follow-Up	Post-Market Performance Follow-Up
Focus	Clinical safety and performance in patients	Analytical and clinical performance, scientific validity
Evaluation context	Clinical evaluation (Annex XIV Part A)	Performance evaluation (Annex XIII Part A)
Study types	Clinical investigations, registries, surveys	Performance studies, proactive gathering of clinical and analytical data
Specific considerations	Patient safety endpoints, benefit-risk	Sensitivity/specificity, positive/negative predictive values, diagnostic accuracy, lot-to-lot consistency
Risk classification	Class I, IIa, IIb, III	Class A, B, C, D
Reporting	PMCF evaluation report feeds into CER, PSUR	PMPF evaluation report feeds into performance evaluation report, PSUR

Practical Implications for IVD Manufacturers

IVD manufacturers transitioning from the IVDD to the IVDR face PMPF requirements that are qualitatively new. Under the IVDD, there was no equivalent to the structured PMPF plan and report. The IVDR creates requirements analogous to the MDR's PMCF framework, but with an IVD-specific focus on analytical performance (sensitivity, specificity, accuracy, precision, lot-to-lot variability) and clinical performance (diagnostic sensitivity and specificity in the intended population).

For IVD manufacturers, the PMPF plan should address:

• Ongoing monitoring of analytical performance through internal quality control data, external quality assessment (EQA) / proficiency testing results, and customer performance complaints
• Monitoring of clinical performance through literature surveillance, post-market performance studies, and analysis of discordant results
• Specific attention to the impact of new biomarkers, assay methodologies, or clinical guidelines on the device's scientific validity

Conclusion

PMCF under the EU MDR is not an afterthought. It is a core regulatory obligation that demands the same level of strategic planning, scientific rigor, and organizational commitment as pre-market clinical evaluation. The manufacturers who treat PMCF as a continuous, integrated process — not a compliance checkbox — will be best positioned for successful Notified Body assessments, efficient CER maintenance, and ultimately, safer devices on the market.

The key takeaways:

• Every device needs a PMCF plan. No exceptions. Proportionality applies to the scope and depth of activities, not to the existence of the plan itself.
• Use the MDCG 2020-7 and 2020-8 templates. They represent the Notified Body's expectations. Align your documents to them.
• Define acceptance criteria upfront. Vague PMCF plans generate deficiency findings. Measurable, specific criteria tied to GSPRs and residual risks are essential.
• Integrate PMCF with CER, risk management, and PMS. Silos create compliance gaps. Build processes that ensure PMCF findings flow into CER updates, risk management re-assessments, and PSURs.
• Plan for the long term. For implantable and Class III devices, PMCF is a multi-year commitment. Build it into product lifecycle budgets and timelines from the start.
• Close evidence gaps for legacy devices. The transition from MDD to MDR is the moment to address clinical evidence deficiencies. PMCF is a primary mechanism for doing so.

The regulatory framework is clear. The Notified Body expectations are documented. The path forward is execution.